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On-Clopidogrel
Platelet Reactivity
A Target in Sight?*
Stephen D. Wiviott, MD,†
Willibald Hochholzer, MD†‡
Boston, Massachusetts; and Bad Krozingen, Germany
Clopidogrel blocks the P2Y12 adenosine diphosphate recep-
or on platelets and, when given in addition to aspirin, has
een shown to reduce cardiovascular events in patients with
cute coronary syndromes (ACS) (1,2). Current guidelines
ecommend the use of clopidogrel 75 mg daily for up to 1
ear after ACS (3) and between 1 and 6 months after
lective percutaneous coronary intervention (PCI), depend-
ng on stent type, with an option of at least 12 months for
atients who are not at high risk of bleeding (4).
The efficacy of such treatment is influenced by the large
nterindividual variability in the pharmacodynamic response
o clopidogrel (5,6). Several clinical studies have demon-
trated the impact of this variability on clinical outcomes
7). Patients with high residual platelet reactivity on clopi-
ogrel are at increased risk for stent thrombosis and other
ajor cardiac complications (7).
See page 1945
The use of platelet function testing in risk stratification
has limitations: most data on variability in response to
clopidogrel and clinical outcome are single-center experi-
ences, making the generalizability of the findings uncertain.
Some of the assays used in studies are not widely available,
are not standardized, or need qualified laboratory staff to
implement. These issues have been barriers to widespread
adoption of testing.
In this issue of the Journal, Brar et al. (8) present a
eta-analysis of the association of platelet function to
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Hochholzer receives consulting income from Sanofi-Aventis.clinical outcome. This study adds to the current literature
beyond simple confirmation. Each of the studies used the
same automated bedside assay and therefore allows pooling
of data, providing power for key outcomes assessments.
Second, the threshold of platelet reactivity in relation to
outcomes is consistent between cohorts and previous data,
providing evidence for a reasonable clinical cut-point (230
platelet reaction units). As with other good meta-analyses, the
increased sample size allows for analysis of patient subgroups
demonstrating consistency across presenting syndromes.
There are some limitations as well. There may be publi-
cation bias with studies failing to show such a correlation
either not being submitted or not published. That could
have substantial implications given the modest sample size
of even the meta-analysis. In addition, most of the data
relates to only half of the clinical question of association
with outcomes—limited information is provided about the
relationship of platelet function and bleeding risk.
This analysis further establishes that on-treatment plate-
let reactivity is a marker of risk among clopidogrel-treated
patients. The widespread adoption of platelet function
testing as part of clinical practice would certainly be has-
tened by demonstrating that therapies cannot only alter this
factor but also improve clinical outcome. That has proved
elusive. Several trials have examined this question or are
currently doing so. Most have the same significant limita-
tions—inadequate sample size or modest therapeutic inter-
vention to high on-treatment reactivity. The largest trial
reported to date, the GRAVITAS (Gauging Responsive-
ness With a VerifyNow Assay–Impact on Thrombosis and
Safety) trial suffered from both of these limitations (9). In
the GRAVITAS trial, high-dose clopidogrel did not reduce
the incidence of ischemic events, although event rates were
low in both arms, and the separation in platelet reactivity
between the standard and the experimental arms was small.
The TRIGGER-PCI (Testing Platelet Reactivity in Pa-
tients Undergoing Elective Stent Placement on Clopidogrel
to Guide Alternative Therapy With Prasugrel) trial ran-
domly assigned subjects with a high platelet reactivity on
clopidogrel after successful implantation of drug-eluting
stents to either standard dose prasugrel or clopidogrel. This
trial likely would have resulted in a greater separation of
platelet function results in the experimental arms than the
GRAVITAS trial, but was terminated for low event rates
and, therefore, inadequate sample size. In both of these
studies, randomization occurred after PCI—after the time
of greatest thrombotic risk had passed. These results,
therefore, do not negate the importance of high on-
clopidogrel platelet reactivity, but suggest that to adequately
test this concept, it would require more, higher-risk sub-
jects, and creative design that allows for differentiation of
therapies at the time they are most likely to be effective.
Three trials of more intensive inhibition of the P2Y12
receptor—the CURRENT–OASIS 7 (Clopidogrel Optimal
Loading Dose Usage to Reduce Recurrent Events–Optimal
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TIMI 38 (Trial to Assess Improvement in Therapeutic Out-
comes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis In Myocardial Infarction), and the PLATO
(Study of Platelet Inhibition and Patient Outcomes)—all
generally support that greater inhibition of platelet aggregation
reduces cardiovascular ischemic events and increases bleeding
compared to standard clopidogrel treatment (10–12). That
provides further circumstantial evidence that treating to lower
levels of platelet inhibition could improve ischemic outcomes.
Nearly every paper about the relationship between plate-
let function testing and clinical outcomes—and every edi-
torial written about such papers—concludes with a remark
that the gap needs to be bridged between treatments that
inhibit P2Y12 receptors (the therapy) and platelet function
tests (the risk marker) and clinical outcomes. If one draws a
parallel to another risk marker (low-density lipoprotein
[LDL] cholesterol) and therapy (HMG-CoA reductase
inhibitors, or statins) an inconsistency emerges. Several
studies—PROVE IT–TIMI 22 (Pravastatin or Atorvastatin
Evaluation and Infection Therapy–Thrombolysis In Myo-
cardial Infarction 22), TNT (Treating to New Targets), A
to Z (Aggrastat to Zocor), SEARCH (Study of the Effec-
tiveness of Additional Reductions in Cholesterol and Ho-
mocysteine), IDEAL (Incremental Decrease in Endpoints
Through Aggressive Lipid Lowering), and others (13)—
also generally show that treating with a higher intensity
HMG-CoA reductase inhibitor improves clinical outcomes
compared to treating with similar drugs with less intensity.
Strictly speaking, PROVE IT–TIMI 22 (for example)
demonstrated that the use of atorvastatin 80 mg after acute
coronary syndromes improved ischemic outcomes compared
to pravastatin 40 mg; it did not demonstrate that achieving
LDL70 mg/dl improves outcomes (14). In fact, in clinical
practice—and in guidelines—the interpretation of these
studies has not been that one should use a specific dose of a
specific statin on the basis of a specific trial; rather, that we
should treat to particular targets of a surrogate measure
(LDL) of statin effect (15,16). Therefore, if we can treat to
70 mg/dl with a generic statin, clinicians generally feel
satisfied that they have met guideline-based targets and also
saved the health care system or patient money.
Why, then, the difference in interpretation of largely similar
data sets between LDL cholesterol and platelet function
testing? First, perhaps because LDL is a better-established risk
marker from epidemiologic studies that clinicians can rapidly
and consistently measure and are comfortable with the mean-
ing and ranges of the results. This understanding has been
accelerated by meta-analyses correlating LDL changes with
clinical benefit (17,18). The data from the Brar et al. (8)
meta-analysis and the growing platelet literature begin to
similarly address this issue for on-treatment platelet reactivity.
Secondly, there are several effective statins that have long-term
safety experience. There is less comfort and clinical experience
with high-dose clopidogrel, prasugrel, or ticagrelor. Impor-
tantly, severe bleeding events (the major side effect of intensiveantiplatelet therapy) occur at a higher frequency than do severe
side effects of statins such as liver failure or rhabdomyolysis.
Therefore, targeting more intense platelet inhibition requires a
greater consideration of the risk/benefit ratio. Clinical research
should continue to address the relationship between on-
treatment reactivity and bleeding risk, not just ischemic risk.
As similar economic pressures arise when clopidogrel
becomes generic compared to newer branded therapies, will
we be pushed by payers, or choose in balancing cost, to
perform a similar leap of faith? As evidence-based practi-
tioners, we select therapies on the basis of major clinical trial
results. We would like to see studies funded and performed
that adequately address the gap between achieved platelet
function and clinical outcomes. Although additional trials
are ongoing, we do not anticipate that the desired evidence
will be available soon. We believe that future economic
pressures may force an increase in the use of platelet
function testing without the highest level of direct evidence.
We are fortunate that we have data such as the analysis by
Brar et al. (8) in this issue of the Journal to better understand
the meaning of the results of these tests.
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